JAK1 and psoriasis: These anti‐inflammatory effects align with findings from studies using JAK1–3 inhibitors (e.g., tofacitinib) in chronic inflammatory conditions such as ulcerative colitis and psoriasis, where JAK inhibition reduced inflammation [13, 34, 35, 36].